Long Term Safety Study of Tanezumab in Chronic Low Back Pain
NCT00924664
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
849
Enrollment
INDUSTRY
Sponsor class
Stopped
See termination reason in detailed description.
Conditions
Low Back Pain
Interventions
BIOLOGICAL:
Tanezumab 20 mg
BIOLOGICAL:
Tanezumab 10 mg
Sponsor
Pfizer